SCHEMBL26078346

SCHEMBL26078346

Clc1ccc(CC2=NCCN2)c(-c2cccs2)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ADRA1A P35348 5/20 0.51
▸ ADRA1D P25100 4/20 0.51
▸ ADRA1B P35368 4/20 0.51
▸ NISCH Q9Y2I1 2/20 0.46
▸ TAAR1 Q96RJ0 6/20 0.44
▸ ADRA2A P08913 4/20 0.41
▸ ADRA2B P18089 4/20 0.41
▸ ADRA2C P18825 4/20 0.41
▸ HTR1B P28222 3/20 0.41
▸ HTR1D P28221 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ CYP2D6 P10635 2/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ HTR1A P08908 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ OPRM1 P35372 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17887759 0.85 ADRA1A (0.51) ADRA1AADRA1DADRA1BNISCHTAAR1
SCHEMBL26078343 0.81 ADRA1A (0.51) ADRA1AADRA1DADRA1BNISCHTAAR1
SCHEMBL26078491 0.80 TAAR1 (0.51) ADRA1AADRA1DADRA1BNISCHTAAR1
SCHEMBL26078349 0.80 ADRA1A (0.48) ADRA1AADRA1DADRA1BNISCHTAAR1
SCHEMBL26078355 0.80 ADRA1A (0.53) ADRA1AADRA1DADRA1BNISCHTAAR1
SCHEMBL26078344 0.77 ADRA1A (0.55) ADRA1AADRA1DADRA1BNISCHTAAR1
SCHEMBL26078336 0.77 ADRA1A (0.52) ADRA1AADRA1DADRA1BNISCHTAAR1
SCHEMBL26078342 0.76 ADRA1A (0.52) ADRA1AADRA1DADRA1BNISCHTAAR1
SCHEMBL26078348 0.76 ADRA1A (0.51) ADRA1AADRA1DADRA1BNISCHTAAR1
SCHEMBL26078337 0.76 ADRA1A (0.51) ADRA1AADRA1DADRA1BNISCHTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312524-A1 ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE CURASEN THERAPEUTICS, INC. 2023-10-05 — — US disclosed
US-20230312524-A1 ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE CURASEN THERAPEUTICS, INC. 2023-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312524-A1 ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE ADRA1A, ADRB1, ADRA1D ADRA1A 1/4885ADRA1D 3/4885ADRA1B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback